• Institution: LOCKSS
LOCKSS

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

Figure 5
Figure 5

Relative expression of mRNAs and median fold changes (horizontal bars) of (a) type I IFN-α subtypes, (b) other members of the type I IFNs and IFN-α receptors, and (c) TNF-α, IFN-ω, and IFN-ω receptors in WB of SLE patients compared with healthy controls (Formula for all). Averages of relative mRNA levels of these cytokines and their receptors in WB from 24 healthy donors were scaled to 1 based on TaqMan QRT-PCR assays. IFN = interferon; QRT-PCR = quantitative real-time reverse transcriptase polymerase chain reaction; SLE = systemic lupus erythematosus; TNF-α = tumor necrosis factor.

This Article

  1. Hum Genomics Proteomics vol. 1 no. 1